UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000039591
Receipt number R000045150
Scientific Title A confirmation study of bowel control effect by consumption of the test food
Date of disclosure of the study information 2021/02/28
Last modified on 2021/02/24 10:07:13

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A confirmation study of bowel control effect by consumption of the test food

Acronym

A confirmation study of bowel control effect by consumption of the test food

Scientific Title

A confirmation study of bowel control effect by consumption of the test food

Scientific Title:Acronym

A confirmation study of bowel control effect by consumption of the test food

Region

Japan


Condition

Condition

Healthy adults

Classification by specialty

Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

The aim of this study is confirmation of bowel control effect for constipation tendency subjects by consumption of the test food.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Defecation status (defecation frequency, defecation days, Bristol Stool Sclae)

Key secondary outcomes

*Defecation status (smell of stool, color of stool, volume of stool, exhilaration by defecation, abdominal symptoms)
* Analysis of organic acids content in stool
* Stool properties (pH of stool, water content of stool)
* Analysis of stool ammonia
* Intestinal microbiota (Analysis by sequencing of amplicons)
* Incidence of adverse events and of side effects


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Prevention

Type of intervention

Food

Interventions/Control_1

Intake one capsule of the test food a day for two weeks

Interventions/Control_2

Intake one capsule of the control food a day for two weeks

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

65 years-old >

Gender

Male and Female

Key inclusion criteria

1)Healthy males and females aged over 20 to under 65 when informed consent.
2)Subjects who are defecated tendency (their defecation frequency are 3 to 5 times a week)
3)Subjects who receive enough explain of the test, who deeply understanding of the test, and who obtain own consent to participate the test.

Key exclusion criteria

1) Subjects who constantly eat seaweeds like simmered laver in sweetened soy sauce etc., or subjects who can't restrict eat them during test period.
2) Subjects who are given continuous treatment by taking medicines.
3) Subjects who intaking Food for Specified Health Uses (FOSHU), food with function claims and/or health food, those having possibility of defecation improvement or soft stool improvement, more than three days a week.
4) Females who are pregnant or lactating, and females who could become pregnant or lactating during test period.
5) Subjects who have previous and/or current medical history of serious disease (e.g., heart, liver, kidney, digestive organ).
6) Subjects who excessive alcohol intake.
7) Subjects who have extremely irregular dining habits, and subjects who have midnight work or irregular shift work.
8) Subjects who have previous medical history of drug and/or food allergy.
9) Subjects who are participating the other clinical tests. Subjects who participated within 4-weeks prior to the current study and/or who plan to participate the other clinical tests.
10) Subjects who donated over 200mL blood and/or blood components within the last one month to the current study.
11) Males who donated over 400mL blood and/or blood components within the last three months to the current study.
12) Females who donated over 400mL blood and/or blood components within the last four months to the current study.
13) Males who will be collected over 1200mL blood and/or blood components, when the sampling amounts within the last twelve months are adding to the planned sampling amounts of this study.
14) Females who will be collected over 800mL blood and/or blood components when, the sampling amounts within the last twelve months are adding to the planned sampling amounts of this study.
15) Others who have been determined ineligible by principal investigator or sub-investigator.

Target sample size

40


Research contact person

Name of lead principal investigator

1st name Masahiro
Middle name
Last name Terasawa

Organization

KONAN CHEMICAL MANUFACTURING CO., LTD.

Division name

Healthcare Business Dept.

Zip code

510-0103

Address

1515 Kitagomizuka, kusu-cho, Yokkaichi-city, Mie-Perf., 510-0103, Japan

TEL

059-397-2612

Email

terasawa@konanchemical.co.jp


Public contact

Name of contact person

1st name Mitsuhiro
Middle name
Last name Fujimoto

Organization

CPCC Company Limited

Division name

Planning & Sales Department

Zip code

101-0047

Address

4F Sanwauchikannda Building, 3-3-5 Uchikanda Chiyoda-ku, Tokyo 101-0047, Japan

TEL

03-5297-3112

Homepage URL


Email

cpcc-contact@cpcc.co.jp


Sponsor or person

Institute

CPCC Company Limited

Institute

Department

Personal name



Funding Source

Organization

KONAN CHEMICAL MANUFACTURING CO., LTD.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Institutional Review Board of Chiyoda Paramedical Care Clinic

Address

2F Sanwauchikannda Building, 3-3-5 Uchikanda Chiyoda-ku, Tokyo 101-0047, Japan

Tel

03-5297-5548

Email

IRB@cpcc.co.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2021 Year 02 Month 28 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2020 Year 02 Month 25 Day

Date of IRB

2020 Year 02 Month 21 Day

Anticipated trial start date

2020 Year 02 Month 28 Day

Last follow-up date

2020 Year 04 Month 17 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2020 Year 02 Month 25 Day

Last modified on

2021 Year 02 Month 24 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000045150


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name